Our
Latest News
Our
Past Releases
Edinburgh: November 2023
NuCana Participated in the Truist Securities 2023 BioPharma Symposium
Edinburgh: October 2023
NuCana Presented Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
Edinburgh: October 2023
NuCana Presented Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
Edinburgh: September 2023
NuCana Announced Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
Edinburgh: August 2023
NuCana Reported Second Quarter 2023 Financial Results and Provides Business Update
Edinburgh: June 2023
NuCana Presented at the Jefferies Healthcare Conference
Edinburgh: May 2023
NuCana Reported First Quarter 2023 Financial Results and Provides Business Update
Edinburgh: May 2023
NuCana Announced Receipt of Nasdaq Notice
Edinburgh: April 2023
NuCana Presented Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
Edinburgh: April 2023
NuCana Reported Fourth Quarter and Year-End 2022 Financial Results and Provided Business Update
Edinburgh: March 2023
Technical Board of Appeal of the European Patent Office Issued Oral Ruling that NuCana’s ‘190 Patent is Not Valid
Edinburgh: February 2023
NuCana Participated in Two Investor Conferences
Edinburgh: January 2023
NuCana Regained Compliance with Nasdaq Minimum Bid Price Requirement
Edinburgh: January 2023
NuCana Announced Receipt of NASDAQ Notice
Edinburgh: January 2023
NuCana Hosted Investor Meetings During the J.P. Morgan Healthcare Conference
Edinburgh: November 2022
NuCana Reported Third Quarter 2022 Financial Results and Provided Business Update
Edinburgh: November 2022
NuCana to Presented at the Jefferies London Healthcare Conference
Edinburgh: October 2022
NuCana Presented Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022
Edinburgh: September 2022
NuCana Presented Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022
Edinburgh: September 2022
NuCana Presented Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022
Edinburgh: September 2022
NuCana Presented at the European Society for Medical Oncology (ESMO) Congress 2022
Edinburgh: September 2022
NuCana Participated in Citi's 17th Annual BioPharma Conference
Edinburgh: August 2022
NuCana Reported Second Quarter 2022 Financial Results and Provided Business Update
Edinburgh: July 2022
NuCana Regained Compliance with Nasdaq Minimum Bid Price Requirement
Edinburgh: July 2022
German Court Ruled that Gilead's Sofosbuvir Infringes NuCana's '190 Patent
Edinburgh: June 2022
NuCana Presented on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress
Edinburgh: June 2022
NuCana Announced Receipt of NASDAQ Notice
Edinburgh: June 2022
NuCana Reported First Quarter 2022 Financial Results and Provided Business Update
Edinburgh: June 2022
NuCana Participated in the 2022 Jefferies Healthcare Conference
Edinburgh: April 2022
NuCana Reported Fourth Quarter and Year Ended 2021 Financial Results and Provided Business Update
Edinburgh: March 2022
NuCana Presented on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022
Edinburgh: March 2022
NuCana Announced Update for Phase 3 Biliary Tract Cancer Study
Edinburgh: February 2022
NuCana Participated in Two Investor Conferences
Edinburgh: February 2022
NuCana Announced Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study
Edinburgh: November 2021
NuCana Reported Third Quarter 2021 Financial Results and Provides Business Update
Edinburgh: November 2021
NuCana Presented at the Jefferies 2021 London Healthcare Conference
Edinburgh: November 2021
NuCana Appointed Elliott M. Levy, M.D. to its Board of Directors
Edinburgh: September 2021
NuCana Received Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer
Edinburgh: September 2021
NuCana Announced Four Poster Presentations at the ESMO Congress 2021
Edinburgh: September 2021
NuCana Announced Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study
Edinburgh: September 2021
NuCana Participated in Three Upcoming Investor Conferences
Edinburgh: August 2021
NuCana Reported Second Quarter 2021 Financial Results and Provides Business Update
Edinburgh: August 2021
NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer
Edinburgh: May 2021
NuCana Presented at the Jefferies Virtual Healthcare Conference
Edinburgh: May 2021
NuCana Reported First Quarter 2021 Financial Results and Provides Business Update
Edinburgh: April 2021
NuCana Participated in the 7th Annual Truist Securities Life Sciences Summit
Edinburgh: April 2021
NuCana Announced Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Edinburgh: March 2021
NuCana Reported Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update
Edinburgh: February 2021
NuCana Participated in Three Investor Conferences
Edinburgh: January 2021
NuCana Presented Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
Edinburgh: December 2020
NuCana Appointed Andrew Kay as Board Chairman
Edinburgh: November 2020
Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist
Edinburgh: November 2020
NuCana Reported Third Quarter 2020 Financial Results and Provided a Business Update
Edinburgh: October 2020
NuCana Expanded its Board of Directors with the Appointment of Bali Muralidhar
Edinburgh: September 2020
NuCana Presented Three Posters at the ESMO Virtual Congress 2020
Edinburgh: September 2020
NuCana Announced Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
Edinburgh: September 2020
NuCana Announced Pricing of a Public Offering of American Depositary Shares
Edinburgh: September 2020
NuCana Announced Proposed Public Offering of American Depositary Shares
Edinburgh: August 2020
NuCana Reported Second Quarter 2020 Financial Results and Provides Business Update
Edinburgh: May 2020
NuCana Announced the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic
Edinburgh: May 2020
NuCana Reported First Quarter 2020 Financial Results and Provided Business Update
Edinburgh: May 2020
NuCana Presented Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020
Edinburgh: May 2020
NuCana Announced Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)
Edinburgh: April 2020
NuCana Provided Update on Impact of COVID-19 on Clinical Studies
Edinburgh: March 2020
NuCana Reported Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
Edinburgh: March 2020
NuCana Reported Fourth Quarter and Year-End 2019 Financial Results and Provided Business Update
Edinburgh: March 2020
NuCana Received Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer
San Francisco: January 2020
NuCana Announced First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer
Edinburgh: November 2019
NuCana Participated in the Piper Jaffray 31st Annual Healthcare Conference
Edinburgh: November 2019
NuCana Presented at the Jefferies 2019 London Healthcare Conference
Edinburgh: November 2019
NuCana Reported Third Quarter 2019 Financial Results and Provided Business Update
Boston: October 2019
NuCana Presented Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Edinburgh: October 2019
NuCana Announced FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer
Edinburgh: August 2019
NuCana Presented at the Morgan Stanley 17th Annual Global Healthcare Conference
Edinburgh: August 2019
NuCana Participated in Citi’s 14th Annual Biotech Conference
Edinburgh: August 2019
NuCana Reported Second Quarter 2019 Financial Results and Provided Business Update
Liverpool: August 2019
Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study Acelarate Has Been Suspended Following a Prespecified Futility Analysis
Edinburgh: July 2019
NuCana Announced First Patients Dosed in Phase I Study of NUC-7738
Edinburgh: June 2019
NuCana Received Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer
Edinburgh: May 2019
NuCana Reported First Quarter 2019 Financial Results and Provided Business Update
Edinburgh: May 2019
NuCana Presented at the Jefferies 2019 Healthcare Conference
Edinburgh: April 2019
NuCana Participated in the William Blair 3rd Late-Stage Therapeutics Conference
Edinburgh: March 2019
NuCana Reported Fourth Quarter and Year-End 2018 Financial Results and Provided Business Update
Edinburgh: March 2019
NuCana Presented at the Cowen and Company 39th Annual Health Care Conference
Edinburgh: February 2019
NuCana Presented at the American Association for Cancer Research (AACR) Annual Meeting 2019
Edinburgh: January 2019
NuCana Announced Withdrawal of Public Offering of ADSs
Edinburgh: January 2019
NuCana Announced Proposed Public Offering of ADSs
Edinburgh: November 2018
NuCana Announced First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer
Edinburgh: November 2018
NuCana Reported Third Quarter 2018 Financial Results and Provided Business Update
Edinburgh: November 2018
NuCana Participated in Citi's 2018 Global Healthcare Conference
Edinburgh: November 2018
NuCana Participated in the 2018 Evercore ISI HealthCONx Conference
Edinburgh: November 2018
NuCana Participated in the Jefferies 2018 London Healthcare Conference
Edinburgh October 2018
NuCana Presented Data from Phase I Study of NUC-3373 at ESMO 2018
Edinburgh: October 2018
NuCana Reported Additional Promising Clinical Data on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018
Edinburgh: October 2018
NuCana Presented New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress
Edinburgh: August 2018
NuCana Participated in Citi's 13th Annual Biotech Conference.
Edinburgh: August 2018
NuCana Reported Second Quarter 2018 Financial Results and Provided Business Update
Additional Acelarin and NUC-3373 Data to be Presented at ESMO in October
Edinburgh: May 2018
NuCana CEO Hugh Griffith Honoured with the Outstanding Achievement Award From Life Sciences Scotland, NuCana also awarded Investment of the Year at awards gala in Glasgow.
Edinburgh: May 2018
NuCana Announced Appointment of Cyrille Leperlier to its Board of Directors
Edinburgh: May 2018
NuCana Reported First Quarter 2018 Financial Results
New York: May 2018
NuCana Participated in the Jefferies 2018 Global Healthcare Conference
Edinburgh: April 2018
NuCana Announced Appointment of Adam George to its Board of Directors
Edinburgh: March 2018
NuCana Reported Financial Results for the Year Ended December 31, 2017
Edinburgh: March 2018
NuCana Participated in the Cowen and Company 38th Annual Health Care Conference
Edinburgh: January 2018
NuCana Announced Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-line Treatment of Advanced Biliary Tract Cancer
Edinburgh: November 2017
NuCana Participated in the Evercore ISI Biopharma Catalyst / Deep Dive Conference
Edinburgh: November 2017
NuCana Announced First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer
Edinburgh: November 2017
NuCana Presented at the Jefferies 2017 London Healthcare Conference
Edinburgh: October 2017
NuCana Announced Closing of Initial Public Offering of ADSs and Exercise of Underwriters’ Option to Purchase Additional ADSs
Edinburgh: September 2017
NuCana Announced Pricing of Initial Public Offering
Edinburgh: September 2017
NuCana Announced Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373 and Received Best Poster Presentation Award at ESMO 2017
Edinburgh: September 2017
NuCana Announced Positive Results of NUC-1031 (Acelarin®) in Advanced Ovarian Cancer at ESMO 2017
Boston: March 2017
NuCana Presented at the Cowen & Company 37th Annual Healthcare Conference
New York: February 2017
NuCana Participated in the LEERINK Partners 6th Global Healthcare Conference
San Francisco: January 2017
Boston: November 2015
NuCana Presented Exciting Data on Novel Anti-Cancer Agent, NUC-3373, at the AACR-NCI-EORTC Conference
Edinburgh: July 2015
NuCana Appointed Professor Chris McGuigan as Chief Scientific Officer
Chicago: May 2015
NuCana Presented Ground-Breaking Final Results of the First in Human Phase I/II Study with Acelarin in Advanced Solid Tumours at the ASCO 51st Annual Meeting
Chicago: May 2015
Acelarin achieved Very High Disease Control Rates in Patients with Advanced Gynaecological Cancers in a Phase I/II Setting. Study Results Presented at the ASCO 51st Annual Meeting
Philadelphia: April 2015
NuCana Presented Data on the Molecular Diagnostics Programme for Acelarin at the AACR Annual Meeting
Edinburgh: December 2014
NuCana Appointed Dr. Paolo Paoletti to its Board of Directors
Chicago: May 2014
Acelarin Achieved High Disease Control Rate in Patients with Advanced Cancer.ProGem1 Study Results Presented at the ASCO 50th Annual Meeting
Edinburgh: April 2014
NuCana Announced a Series B Financing of $57 Million to Fund Expansion of Clinical Studies with its Anti-Cancer ProTides
San Diego: April 2014
NuCana Presented Exceptional Data for Anti-Cancer Agent, Acelarin, at the AACR Annual Meeting
San Diego: March 2014
NuCana Presented at AACR
Edinburgh: February 2014
Important Results of NuCana’s lead ProTide published in prominent scientific journal
Edinburgh: September 2013
NuCana Attended ESMO 2013 in Amsterdam
Edinburgh: July 2013
NuCana Highlighted EvaluatePharma Report Valuing the Industries Pipeline Products. ProTide Technology Takes Number One Position
Cardiff: June 2013
'Drug hunter' Chris McGuigan on NuCana and Medical Research Excitement
Chicago: June 2013
Encouraging Results from the ProGem1 Study of Acelarin (NUC-1031) in Patients with Advanced Cancer Presented at ASCO 2013
Edinburgh: May 2013
NuCana Presented Phase I Clinical Data at ASCO 2013
Edinburgh: April 2013
NuCana Presented at BioEquity Europe
Edinburgh: April 2013
NuCana Appointed Erwan Lejeune as Scientific Affairs Manager.
Edinburgh: March 2013
NuCana Presented at BioTrinity
Edinburgh: February 2013
NuCana Ups and Downs of a Drug Hunter - from the Lab to Patients
A lecture by Prof. Chris McGuigan as Part of the 'Science in Health' Public Lecture Series at Cardiff University
Edinburgh: February 2013
NuCana - Pioneering Pair Invest in a Healthy Future.
Edinburgh: February 2013
NuCana Biomed Announced as Joint Winners of the Investment of the Year (2012) Award.
Edinburgh: February 2013
NuCana Joint Winners of the Investment of the Year (2012) Award
Edinburgh: November 2011
NuCana Secured $10.4 million Series A Financing to Accelerate it's ProTide Anti-Cancer Drugs into Clinical Development
International: November 2011
NuCana Gets $10.5M for ProTide Cancer Drugs
Scotland: November 2011
Life Science Specialists £6.7m for New Venture
Wales: November 2011
Welsh Scientists Could Prevent Cancer Cells Becoming Resistant to Drugs
Edinburgh: February 2011
NuCana Announced it had Completed a Further Equity Financing that will Enable NuCana's First Product to Enter Clinical Development
Edinburgh: February 2011
Hugh Griffth was a Keynote Speaker at the Prestigious Scottish Enterprise Life Sciences Annual Dinner
Cardiff: January 2011
Chris Wood Presented at Cardiff University EPSRC/PRESIDENTS ENTREPRENEURSHIP DAY on Discovering New Medicines & Making Money
Edinburgh: December 2010
NuCana Announced the Appointment of Martin Mellish as Non Executive Director to the Board of Directors
Edinburgh: June 2010
Hugh Griffith was Guest Speaker at BIA and Ernst & Young Beyond Borders
Seminar
Edinburgh: May 2010
Hugh Griffith Provided a Vision for Challenges Facing Biotechnology in the Foreword to Marks & Clerk Life Sciences Report 2010
Cardiff: April 2010
Christopher Wood Presented at Wales Cancer Conference
Edinburgh: February 2010
Hugh Griffith Presented at BIA Scotland BioLeadership Forum and Dinner
Edinburgh: December 2009
NuCana Completed Financing to Expand Anti-Cancer Drug Development Programme.
Edinburgh: December 2009
Alida Capital International Completed Financing into NuCana BioMed.
Cardiff: November 2009
Morvus Technology and NuCana Signed Exclusive World-wide Licence to Develop ProTide Technology in Cancer.
Our
Past Events
Edinburgh: November 2023
NuCana Participated in the Truist Securities 2023 BioPharma Symposium
Edinburgh: October 2023
NuCana Presented Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
Edinburgh: October 2023
NuCana Presented Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
Edinburgh: June 2023
NuCana Presented at the Jefferies Healthcare Conference
Edinburgh: April 2023
NuCana Presented Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
Edinburgh: February 2023
NuCana Participated in Two Investor Conferences
Edinburgh: January 2023
NuCana Hosted Investor Meetings During the J.P. Morgan Healthcare Conference
Edinburgh: November 2022
NuCana to Presented at the Jefferies London Healthcare Conference
Edinburgh: October 2022
NuCana Presented Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022
Edinburgh: September 2022
NuCana Presented Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022
Edinburgh: September 2022
NuCana Presented Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022
Edinburgh: September 2022
NuCana Presented at the European Society for Medical Oncology (ESMO) Congress 2022
Edinburgh: September 2022
NuCana Participated in Citi's 17th Annual BioPharma Conference
Edinburgh: June 2022
NuCana Presented on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress
Edinburgh: June 2022
NuCana Participated in the 2022 Jefferies Healthcare Conference
Edinburgh: March 2022
NuCana Presented on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022
Edinburgh: February 2022
NuCana Participated in Two Investor Conferences
Edinburgh: November 2021
NuCana Presented at the Jefferies 2021 London Healthcare Conference
Edinburgh: September 2021
NuCana Presented Four Posters at the ESMO Congress 2021
Edinburgh: September 2021
NuCana Participated in Oppenheimer’s Virtual Fall Healthcare Life Sciences & MedTech Summit
Edinburgh: September 2021
NuCana Participated in H.C. Wainwright 23rd Annual Global Investment Conference
Edinburgh: September 2021
NuCana Participated in Citi’s 16th Annual BioPharma Virtual Conference
Edinburgh: May 2021
NuCana Presented at the Jefferies Virtual Healthcare Conference
Edinburgh: April 2021
NuCana Participated in the 7th Annual Truist Securities Life Sciences Summit
Edinburgh: April 2021
NuCana Presented Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2021
Edinburgh: March 2021
NuCana Participated in Oppenheimer's 31st Annual Healthcare Conference
Edinburgh: March 2021
NuCana Participated in H.C. Wainwright Global Life Sciences Conference
Edinburgh: March 2021
NuCana Presented at the Cowen 41st Annual Healthcare Conference
Edinburgh: March 2021
NuCana Presented at the Cowen 41st Annual Healthcare Conference
Edinburgh: November 2020
NuCana Presented at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Edinburgh: November 2020
NuCana Presented at the Jefferies Virtual London Healthcare Conference
Edinburgh: September 2020
NuCana Presented Three Posters at the ESMO Virtual Congress 2020
Edinburgh: August 2020
NuCana Presented at the William Blair Biotech Focus Conference
Edinburgh: June 2020
NuCana Presented at the 2020 Jefferies Virtual Healthcare Conference
Edinburgh: June 2020
NuCana Presented Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020
Edinburgh: May 2020
NuCana Presented at the 2020 Jefferies Virtual Healthcare Conference
Edinburgh: May 2020
NuCana Presented Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020
Boston: February 2020
NuCana Presented at the Cowen and Company 40th Annual Health Care Conference
San Francisco: January 2020
NuCana Participated in the 38th Annual J.P. Morgan Healthcare Conference
Edinburgh: November 2019
NuCana Participated in the Piper Jaffray 31st Annual Healthcare Conference
Edinburgh: November 2019
NuCana Presented at the Jefferies 2019 London Healthcare Conference
Boston: October 2019
NuCana Presented Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
New York: September 2019
NuCana Presented at the Morgan Stanley 17th Annual Global Healthcare Conference
Boston: September 2019
NuCana Participated in Citi’s 14th Annual Biotech Conference
New York: June 2019
NuCana Presented at the Jefferies 2019 Global Healthcare Conference
Edinburgh: April 2019
NuCana Participated in the William Blair 3rd Late-Stage Therapeutics Conference
Boston: March 2019
NuCana Presented at the Cowen and Company 39th Annual Healthcare Conference
Edinburgh: February 2019
NuCana Presented at the American Association for Cancer Research (AACR) Annual Meeting 2019
San Francisco: January 2019
NuCana Participated in the 37th Annual J. P. Morgan Healthcare Conference
Edinburgh: November 2018
NuCana Participated in Citi's 2018 Global Healthcare Conference
Edinburgh: November 2018
NuCana Participated in the 2018 Evercore ISI HealthCONx Conference
London: November 2018
NuCana Presented at the Jefferies 2018 London Healthcare Conference
Munich: October 2018
NuCana Presented New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress
Boston: September 2018
NuCana Participated in Citi’s 13th Annual Biotech Conference
New York: June 2018
NuCana Participated in the Jefferies 2018 Global Healthcare Conference
Chicago: June 2018
NuCana Presented Data at ASCO 2018 Annual Meeting
New York: May 2018
NuCana Participated in the William Blair Late-Stage Therapeutics Conference
Boston: March 2018
NuCana Participated in the Cowen & Company 38th Annual Healthcare Conference
San Francisco: January 2018
NuCana Presented Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer
London: November 2017
NuCana Presented at the Jefferies 2017 London Healthcare Conference
Boston: March 2017
NuCana Presented at the Cowen & Company 37th Annual Healthcare Conference
New York: February 2017
NuCana Participated in the LEERINK Partners 6th Global Healthcare Conference
San Francisco: January 2017
Hugh S. Griffith, CEO Presented at the 35th Annual J.P. Morgan Healthcare Conference
Tokyo: October 2016
Hugh S. Griffith, CEO of NuCana, Presented at the 9th Annual Japan Biopharma Partnering Conference
Boston: September 2016
Hugh S. Griffith, CEO of NuCana, Presented at Citi's 11th Annual Biotech Conference
Chicago: June 2016
NuCana Presented at the American Society of Clinical Oncology
New Orleans: April 2016
NuCana Presented at the American Association for Cancer Research Conference
New York: April 2016
NuCana Presented at the Needham Healthcare Conference
Edinburgh: March 2016
NuCana Presented at Scotsman Life Sciences Conference
New York: February 2016
NuCana Presented at Leerink Partners Global Healthcare Conference
San Francisco: January 2016
Hugh S. Griffith, CEO of NuCana, Presented at the 34th Annual J.P. Morgan Healthcare Conference
New York: December 2015
NuCana’s CEO, Hugh S. Griffith, Presented at the 27th Annual Piper Jaffray Healthcare Conference
Boston: November 2015
NuCana Presented NUC-3373 Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Tokyo: October 2015
Hugh S. Griffith, NuCana’s CEO, Presented at Japan Biopharma Partnering Conference
Cardiff: September 2015
Hugh S. Griffith presented at Tenovus Cancer Care & Life Sciences Research Network Wales Conference at the Life Sciences Hub
Chicago: May 2015
NuCana Presented Results from Acelarin Phase I/II study at the 51st Annual Meeting of the American Society of Clinical Oncology
Philadelphia: April 2015
NuCana Presented Acelarin Molecular Profiling Data at the American Association for Cancer Research Annual Meeting
New York: March 2015
Hugh S. Griffith, NuCana’s CEO, Presented at JMP Securities Life Sciences Conference
Edinburgh: January 2015
Hugh S. Griffith, NuCana’s CEO, Interviewed by BBC
Our
Media Coverage
Scrip: July 2015
ProTide Man Chris McGuigan Hopes to Make NuCana the Next Gilead.
Bioworld Today: June 2015
NuCana Set to Follow “Groundbreaking” ASCO Data with phase III trial.
Fierce Biotech: June 2015
NuCana Readies Suite of Phase III Cancer Trials After Rounding up Mid-phase Data.
ASCO: May 2015
Watch Professor Sarah Blagden Talk About Acelarin at the ASCO (American Society of Clinical Oncology) 51st Annual Meeting.
Financial Times: September 2014
Europe Struggles to Catch US Biotech Bulls.
BioCentury: April 2014
Sofinnova Ventures Led NuCana BioMed Ltd.’s $57 million B round.
BioWorld: April 2014
High Tide for Protides: Nucana Biomed Pulls in $57M Series B.
BBC News - Scotland Business: April 2014
Funding Boost for Life Sciences Firm NuCana BioMed.
Venturewire: April 2014
Sofinnova Ventures Leads $57M Financing for NuCana BioMed.
Edinburgh: February 2013
NuCana Joint Winners of the Investment of the Year (2012) Award